Navigation Links
Studies Presented at Neurology Conference Highlight Early Efficacy,,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron

BOSTON, May 03, 2007 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals announced today the results of three clinical studies with Betaseron(R) (interferon beta-1b), presented this week at the American Academy of Neurology's (AAN) 59th Annual Meeting, demonstrating early efficacy, long-term tolerability, and high patient satisfaction with treatment in patients with relapsing forms of multiple sclerosis (MS).

"Collectively, these studies highlight the important clinical benefits and long-term safety and tolerability of Betaseron treatment," said Ludger Heeck, Ph.D., Vice President and General Manager, Specialized Therapeutics, Bayer HealthCare Pharmaceuticals. "Betaseron is the first immunomodulatory MS treatment shown to significantly delay disability and disease progression in patients with the first event suggestive of MS. In addition, key attributes, such as a high level of patient satisfaction and tolerability of the medication, may help improve a person's adherence to treatment and consequently, the effectiveness of the treatment."

In the first study, known as BENEFIT(1) (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), immediate initiation of Betaseron(R) treatment in patients after a first event suggestive of MS significantly reduced the risk of disability as measured by the Expanded Disability Status Scale (EDSS) by 40 percent(2). The results of the prospectively designed and blinded study were measured over three years and compared early treatment to delayed treatment, defined as receiving treatment after the second clinical event or after two years.

The second study - known as the Betaseron 16-Year Long-Term Follow-up (16- Year LTF) Study(3)- found long-term(4) use of Betaseron to be safe and tolerable. The 16-Year LTF Study followed patients with the relapsing form of MS who had already participated in the pivotal Betaseron trial, the results of which led to t
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:5/13/2008)... III Trial Experience Better, Long-Term Clinical O...ents Treated with TAXUS,...-- Long-term data,presented for the first time tod...l trial studying the XIENCE(TM) V Everolimus Eluti... V continues to deliver clinically superior,benefi...
(Date:5/13/2008)... the Treatment of Inflammatory ...n Payment from Partner GlaxoSmithKline, MOUNTAIN ... Inc., today,announced the initiation of a Phase I...vel small molecule compound designed to specifical...ociated with inflammatory,diseases such as rheumat...
(Date:5/13/2008)...soluble polymer material,designed to stop bone ble...,according to a new animal study just published in...s come on the heels of recently published,research... the risk of,surgical infections., Researchers fr...rleston,and Keck School of Medicine at the Univers...
(Date:5/12/2008)...ion Prevention Business, DUBLIN, Ohio, May 12 /PR...rovider of products and services that improve the ...unced it has completed the,acquisition of assets o...f,infection prevention products sold under the Chl...cts are used widely in U.S. hospitals and,surgery ...
Breaking Medicine Technology:XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 2XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 3XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 4XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 5ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 2Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 3Cardinal Health Completes Enturia Acquisition 2Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 1Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 2Green Tea May Brew Up Healthier Skin 106 1Third Security LLC Hires Two New Managing Directors 110 1Third Security LLC Hires Two New Managing Directors 110 2Web Portal Makes Organ Donation Easy 108 1Web Portal Makes Organ Donation Easy 108 2
(Date:5/13/2008)...exercise helps prevent the disease, two additional...(HealthDay News) -- New research has found both ba...The bad news is a risk factor you can,t change: Wo...r face an increased risk of breast cancer througho...t diagnosis, according to a study in the May 13 is...
(Date:5/13/2008)...gress in patient safety research could slow to a c...issues, Johns Hopkins researchers assert in an upc...paradigm to patient safety research. It just isnt ...ctor for public health at the Johns Hopkins Berman...le. , The piece, published in the June issue of ...
(Date:5/13/2008)...mWater kicks off the summer with SYNERGY Events, ,...ve makeover competition, BOSTON, May 13 /PRNewswi... SYNERGY Events, the premier event planning compan...al live makeover competition. The,competition will...ns on May,16, 2008. Doors open at 8:30 p.m. at the...
(Date:5/13/2008)...AN ANTONIO, Texas, May 13 /PRNewswire/ -- Attorney...list Mormon community in Eldorado, TX,will ask a ...rgency order,to prevent the state from taking away... turns a year old on Thursday., Attorneys are fil...m.,seeking an emergency injunction to keep the Tex...
Breaking Medicine News(10 mins):Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 2Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 3Health News:Treating safety research like other clinical studies slows progress 2Health News:Treating safety research like other clinical studies slows progress 3Health News:TrimWater Keeps Boston Beautiful 2Health News:TrimWater Keeps Boston Beautiful 3Health News:FLDS Couple Seeks Emergency Order to Stop Infant Seizure, Say Perry & Haas 2Health News:FLDS Couple Seeks Emergency Order to Stop Infant Seizure, Say Perry & Haas 3
...ritain of Indian origin hit headlines after conduc...S in the UK is well known for its long waiting lis...efore getting a routine operation. This has brough...arwal of the Worthing and Southlands Hospital in S...
... to find out subtle changes in the motions of the ...nction by using the ultrasounds. They report that ...et o heart damages like the heart attacks.// The r...uld also contribute to optimal adjustment of cardi...
...t enables the malaria parasites to attack the red ...lished in the journal Cell, will help the scientis...se of malaria.// A major pathway through which mal... the binding of a protein on the surface of merozo...
...he first time, researchers have made the first cau...phospholipids and the risk of coronary artery dise...o those of Lp(a) lipoprotein, the researchers sugg...of the latter to promote atherosclerosis may be pa...
Other Medicine News:Health News:Indian Surgeon Conducts 70 Surgeries During His Holidays In England 2Health News:Ultrasounds To Detect Changes In Heart Motions 2Health News:Researchers Discover Protein That Causes Malaria 2Health News:The Link Between Oxidized Phospholipids And Coronary Artery Disease 2
Clearview Strep A Exact uses rapid technology to provide direct detection of Group A Streptococcal antigen from throat swabs. , ,Clearview Strep A Exact uses a patented, innovative technology to
One inch disposable patch electrode uses a specially formulated adhesive solid gel. Reusable lead wire with snap connector provides economic benefits. Ideal for sleep studies where leg movement or EK
Made with elastic fabric, these head cap systems are packaged to provide everything you need to begin testing. Each Electro-Cap System features pure tin electrodes positioned according to the Interna
Made with elastic fabric, these head cap systems are packaged to provide everything you need to begin testing. Each Electro-Cap System features pure tin electrodes positioned according to the Interna
Medicine Products: